Workflow
Lexicon Pharmaceuticals(LXRX)
icon
Search documents
Lexicon Pharmaceuticals(LXRX) - 2023 Q2 - Quarterly Report
2023-08-04 11:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...
Lexicon Pharmaceuticals(LXRX) - 2023 Q2 - Earnings Call Transcript
2023-08-04 02:01
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Inc. Andrew Tsai - Jefferies Group LLC Operator Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Cal ...
Lexicon Pharmaceuticals(LXRX) - 2023 Q1 - Quarterly Report
2023-05-04 11:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...
Lexicon Pharmaceuticals(LXRX) - 2023 Q1 - Earnings Call Transcript
2023-05-03 00:27
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Results Conference Call May 2, 2023 5:00 PM ET Company Participants Carrie Siragusa - Executive Director, Corporate Strategy and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Dr. Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yigal Nochomovitz - Citigroup Joseph Stringer - Needham and Company Operator Good day everyone, and ...
Lexicon Pharmaceuticals(LXRX) - 2022 Q4 - Earnings Call Transcript
2023-03-03 18:32
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Carly Kenselaar – Citi Joseph Stringer – Needham & Company Operator Good afternoon, and welcom ...
Lexicon Pharmaceuticals(LXRX) - 2022 Q4 - Annual Report
2023-03-03 12:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year EndedDecember 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-04 ...
Lexicon Pharmaceuticals(LXRX) - 2022 Q3 - Earnings Call Transcript
2022-11-10 02:34
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Mike Kelly – Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Carly Kenselaar – Citigroup Yasmeen Rahimi – Piper Sandler Joseph Stringer – Needham & Company Operator Good day, ladies and gentlemen. Welcome to the Lexicon Pharmaceuti ...
Lexicon Pharmaceuticals(LXRX) - 2022 Q2 - Earnings Call Transcript
2022-08-03 03:30
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Mike Kelly - Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President & Chief Financial Officer Craig Granowitz - Senior Vice President & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Joseph Stringer - Needham & Company Operator Good afternoon, ladies and gentlemen and welcome to the Lexicon Pharmaceuticals Inc. Second Quarter 2 ...
Lexicon Pharmaceuticals(LXRX) - 2022 Q1 - Earnings Call Transcript
2022-05-05 14:53
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2022 Results Conference Call May 5, 2022 8:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JP Morgan Joseph Stringer - Needham & Company Operator Good morning. This is Jesse, and I will be your conference operator today. At this ti ...
Lexicon Pharmaceuticals(LXRX) - 2021 Q4 - Earnings Call Transcript
2022-02-28 15:40
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2021 Earnings Conference Call February 28, 2022 8:00 AM ET Company Participants Chas Schultz - Executive Director, Corporate Communications and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham Julian Harrison - BTIG Disclaimer*: This transcript is designed to be used alongside the fre ...